BCV
SPRO icon

Banque Cantonale Vaudoise’s Spero Therapeutics SPRO Stock Holding History

Banque Cantonale Vaudoise’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,000
Closed -$1K – 1285
2022
Q2 		$1K Hold
2,000
– – ﹤0.01% 1270
2022
Q1 		$17K Hold
2,000
– – ﹤0.01% 1168
2021
Q4 		$32K Hold
2,000
– – ﹤0.01% 1137
2021
Q3 		$37K Hold
2,000
– – ﹤0.01% 1094
2021
Q2 		$28K Hold
2,000
– – ﹤0.01% 1134
2021
Q1 		$29K Hold
2,000
– – ﹤0.01% 1047
2020
Q4 		$39K Buy
2,000
+1,200
+150% +$18.7K ﹤0.01% 968
2020
Q3 		$9K Buy
+800
New +$9.46K ﹤0.01% 1021

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

Banque Cantonale Vaudoise's SPRO Position: Q3 2022 in Review

Banque Cantonale Vaudoise sold out of Spero Therapeutics (SPRO) in Q3 2022, closing a stake of 2,000 shares — an estimated $1K sold.

Banque Cantonale Vaudoise first reported a position in SPRO in Q3 2020 and held it in 8 quarters. The position peaked at $39K in Q4 2020. 69 funds tracked by Wall St. Rank hold SPRO as of Q3 2022.

  • Banque Cantonale Vaudoise reported no remaining Spero Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 2,000 Spero Therapeutics shares in Q3 2022, an estimated $1K.
  • Banque Cantonale Vaudoise first reported a position in Spero Therapeutics in Q3 2020 and held it in 8 quarters.
  • Banque Cantonale Vaudoise's Spero Therapeutics position peaked at $39K in Q4 2020.
  • 69 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2022.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2022, filed 17 Oct 2022.